Authors explore complexities in scaling gene-therapy production with special attention is to monitoring and enhancing ...
Rising demand for gene and cell therapies, expanding mRNA vaccine pipelines, and increasing investments in GMP-compliant manufacturing facilities are driving growth in the viral vectors and plasmid ...
Jason Luke, MD, FACP, discusses the mechanism of action of IMA203, a novel agent for the treatment of metastatic melanoma. In an interview with Targeted Oncology, Jason Luke, MD, FACP, associate ...
In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma. In part 1 of our interview with ...
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced the signing of a definitive agreement to acquire Mirus Bio for $600 million. This deal is ...
Technologies used for cell and gene therapy development have come a long way but there are still important challenges associated with lentivirus manufacture. GMP plasmids account for a substantial ...
The LV Edge Producer System completely eliminates GMP plasmid cost and greatly reduces process complexity and variability by stably integrating all the genes for lentiviral production into the host ...
Asimov announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production. New off-the-shelf system reduces the cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback